|
Mar 26
|
Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
|
|
Feb 1
|
Health Care Roundup: Market Talk
|
|
Feb 1
|
Roche (RHHBY) 2023 Earnings Miss, COVID-19 Product Sales Down
|
|
Feb 1
|
Roche shuffles early stage pipeline as it joins obesity rush
|
|
Feb 1
|
Roche Expects Sales, Core Earnings Growth
|
|
Feb 1
|
Roche shares fall on modest 2024 outlook
|
|
Feb 1
|
UPDATE 4-Roche sees pick up in growth as it overcomes drop in COVID sales
|
|
Feb 1
|
New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)
|
|
Feb 1
|
New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
|
|
Feb 1
|
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
|
|
Jan 16
|
Merck's Crown Jewel Cancer Drug Keytruda Scores FDA Approval For Third Indication In Cervical Cancer
|
|
Jan 16
|
Roche's (RHHBY) Tecentriq Subcutaneous Gets Approval in the EU
|
|
Jan 16
|
European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
|
|
Jan 12
|
The Zacks Analyst Blog Highlights Roche, Netflix, NIKE, Uber, Technologies and Prologis
|
|
Jan 12
|
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
|
|
Jan 11
|
Top Research Reports for Roche, Netflix & NIKE
|
|
Jan 11
|
Renewables grew rapidly in 2023, but must grow faster still to meet climate change target, IEA says
|
|
Jan 10
|
JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss market
|
|
Jan 10
|
Why Sarepta's (SRPT) Stock Price Moved Up 17% on Tuesday
|
|
Jan 10
|
Swiss Pharma Giants Who Missed Boat on Obesity Fight to Stay Relevant
|